Related Experiment Video

Updated: Apr 16, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis

P Kongtim1, M H Qazilbash1, J J Shah2

  • 1Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Bone Marrow Transplantation
|March 3, 2015
PubMed

Insights

High-dose therapy and auto-SCT (HDT-ASCT) is a viable treatment for light-chain amyloidosis with cardiac involvement. This approach demonstrated manageable treatment-related mortality and improved long-term survival outcomes.

Area of Science:

  • Hematology
  • Cardiology
  • Oncology

Background:

  • Cardiac involvement in light-chain amyloidosis (AL) significantly worsens prognosis.
  • It is associated with increased treatment-related mortality (TRM) and morbidity during high-dose therapy and auto-SCT (HDT-ASCT).

Purpose of the Study:

  • To evaluate the outcomes of patients with cardiac amyloidosis undergoing HDT-ASCT.
  • To identify factors influencing survival in this high-risk patient group.

Main Methods:

  • Retrospective analysis of 30 patients with cardiac amyloidosis who underwent HDT-ASCT.
  • Melphalan-based conditioning regimens (140-200 mg/m²) were utilized.
  • Median follow-up was 35 months.

Main Results:

  • One-year TRM was 10%.
  • Three-year overall survival (OS) and event-free survival (EFS) were 83% and 56.8%, respectively.
  • Cumulative incidence of relapse at 3 years was 38.5%.

Conclusions:

  • HDT-ASCT is well-tolerated in patients with high-risk cardiac amyloidosis.
  • This therapy can lead to improved overall survival outcomes.
  • Age >60, lack of novel induction therapy, and BM plasmacytosis >10% were negative survival factors.

More Related Videos

Intramyocardial Cell Delivery: Observations in Murine Hearts08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

14.2K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
5.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
721
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
920